Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Viral infectious disorders

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44412   clinical trials with a EudraCT protocol, of which   7421   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    65 result(s) found for: Viral infectious disorders. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2011-006132-24 Sponsor Protocol Number: CDEB025A2313 Start Date*: 2012-05-18
    Sponsor Name:Novartis Farmaceutica, S.A.
    Full Title: A multi-centre 3-year follow-up study to assess the viral activity in patients who failed to achieve sustained virologic response in Novartis-sponsored alisporivir studies for chronic hepatitis C p...
    Medical condition: Chronic hepatitis C patients who failed to achieve sustained virologic response (SVR24) on alisporivir or direct-acting antivirals (DAA) in previous Novartis-sponsored studies.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) HU (Prematurely Ended) GB (Completed) PL (Prematurely Ended) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005624-10 Sponsor Protocol Number: OVID-trial Start Date*: 2021-05-06
    Sponsor Name:University Hospital Zurich
    Full Title: ENOXAPARIN FOR PRIMARY THROMBOPROPHYLAXIS IN AMBULATORY PATIENTS WITH CORONAVIRUS: THE MULTICENTER RANDOMIZED CONTROLLED OVID TRIAL
    Medical condition: Patients diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    22.1 10021881 - Infections and infestations 10061229 Lung infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004586-13 Sponsor Protocol Number: 117307 Start Date*: 2014-04-28
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Long-term hepatitis A and B antibody persistence in healthy adult subjects, primed 16 to 20 years earlier with GSK Biologicals’ combined hepatitis A and B vaccine, Twinrix® (SB208127) in study HAB-...
    Medical condition: Healthy volunteers (Vaccination against hepatitis A and hepatitis B in healthy adults)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002748-28 Sponsor Protocol Number: GS-US-248-0131 Start Date*: 2011-11-30
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subject...
    Medical condition: Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000944-43 Sponsor Protocol Number: GS-US-248-0120 Start Date*: 2011-08-09
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly with GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naive Subjects with Chronic Genotype 1 HCV Infection
    Medical condition: Genotype 1 Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    14.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003559-21 Sponsor Protocol Number: CDEB025A2212 Start Date*: 2012-02-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Retrospective Pharmacogenetic Analysis of Hepatitis C Patients treated with Alisporivir (DEB025) Alone or in Combination with Peg-IFN2a and/or Ribavirin
    Medical condition: Hepatitis C and how biomarkers affect the response to treatment of the disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-003710-58 Sponsor Protocol Number: 57238 Start Date*: 2018-07-17
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO “PAOLO GIACCONE” DI PALERMO
    Full Title: Study to Investigate the Efficacy of elbasvir/grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Na¿ve, HCV-Infected Patients With non-severe Fibrosis, with or without glucose abnorm...
    Medical condition: chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003391-74 Sponsor Protocol Number: 106794 Start Date*: 2016-05-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Persistence of hepatitis B antibodies, immunogenicity and safety of GSK Biologicals’ hepatitis B vaccine, Engerix™-B Kinder (SKF103860) challenge dose, in adolescents vaccinated with four doses of ...
    Medical condition: Immunisation against infection caused by all known subtypes of hepatitis B virus.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002821-41 Sponsor Protocol Number: 106793 Start Date*: 2014-01-21
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Persistence of hepatitis B antibodies, immunogenicity and safety of GSK Biologicals’ hepatitis B vaccine EngerixTM-B Kinder (SKF103860) challenge dose in adolescents vaccinated with four doses of I...
    Medical condition: Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004035-88 Sponsor Protocol Number: AntiCov Start Date*: 2021-11-18
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: A randomized, open-label, active controlled, parallel group, multicenter phase 3 study to evaluate the efficacy and tolerability of Bamlanivimab and Etesevimab, Casirivimab and Imdevimab, and Sotro...
    Medical condition: Patients with mild to moderate SARS-COV-2 infection.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000637-39 Sponsor Protocol Number: P7977-2025 Start Date*: 2012-05-17
    Sponsor Name:Gilead Sciences Inc.
    Full Title: An Open-Label Study to Explore the Clinical Efficacy of GS-7977 with Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
    Medical condition: Hepatitis C Virus (HCV) infection (all genotypes) in patients who have been placed on a wait list for liver transplantation from a deceased doner for hepatocellular carcinoma (HCC).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-002245-37 Sponsor Protocol Number: GV28418 Start Date*: 2013-01-16
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MCMV5322A/MCMV3068A FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN HIGH-RISK KIDNEY ALLOGRAFT RECIPIENTS
    Medical condition: Transplant-associated cytomegalovirus (CMV) infection
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    15.0 10021881 - Infections and infestations 10058881 Cytomegalovirus viremia LLT
    15.0 10021881 - Infections and infestations 10047438 Viral infectious disorders HLGT
    15.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    15.0 10021881 - Infections and infestations 10011827 Cytomegaloviral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) BE (Completed) GB (Completed) ES (Completed) DE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000456-42 Sponsor Protocol Number: GS-US-256-0148 Start Date*: 2011-10-04
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS 5885 Alone or in Combination with GS-9451 with Peginterferon Alfa 2a and Ribavirin in Treat...
    Medical condition: Genotype 1 Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    13.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) CZ (Completed) HU (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002848-22 Sponsor Protocol Number: MV-004 Start Date*: 2020-12-03
    Sponsor Name:Meissa Vaccines Inc.
    Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Prophylactic Efficacy of MV-012-968 Against Respiratory Syncytial Virus (RSV) Infection in the Virus Challe...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-003717-18 Sponsor Protocol Number: 215226/VIR-7831-5005 Start Date*: 2021-12-30
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: An open-label, non-comparator, multicenter study to describe the pharmacokinetics (PK), pharmacodynamics (PD; viral load) and safety following a single intravenous or intramuscular dose of sotrovim...
    Medical condition: COVID-19 at high risk of disease progression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    23.1 10021881 - Infections and infestations 10084401 COVID-19 respiratory infection LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-000946-39 Sponsor Protocol Number: GS-US-248-0123 Start Date*: 2011-11-21
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection
    Medical condition: Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed) CZ (Completed) HU (Prematurely Ended) PL (Completed) IT (Completed) AT (Completed) SE (Completed) ES (Completed) EE (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000516-37 Sponsor Protocol Number: TS-020DESE Start Date*: 2021-03-04
    Sponsor Name:TurnSole Biologics Llc
    Full Title: A Phase I/II open-label study for Azacitidine, initiated with a lead-in dose escalation pharmacokinetic Phase I/b part in the 20–50 mg/m2 range to evaluate safety in Hospitalized COVID-19 Patients ...
    Medical condition: COVID-19 patients with confirmed sever viral infection of SARS-COV-2
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10047461 Viral infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001249-26 Sponsor Protocol Number: GS-US-337-1431 Start Date*: 2016-02-12
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection in Gilead-...
    Medical condition: Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001635-27 Sponsor Protocol Number: AB20001 Start Date*: 2020-05-04
    Sponsor Name:AB Science
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Masitinib combined with Isoquercetin, and Best Supportive Care in Hospitalized Patients ...
    Medical condition: Hospitalized Moderate and Severe COVID-19 Patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001788-36 Sponsor Protocol Number: CM-2011-02 Start Date*: 2012-09-07
    Sponsor Name:Cell Medica Ltd.
    Full Title: A Phase I/II study to investigate the safety of Adenovirus specific T cells given to high-risk paediatric patients post allogeneic haematopoietic stem cell transplant (allo-HSCT) to treat reactivat...
    Medical condition: Paediatric allogeneic stem cell transplant recipients at high risk of Adenovirus infection
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10060931 Adenovirus infection PT
    17.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 16 08:35:46 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA